vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与Xeris Biopharma Holdings, Inc.（XERS）财务数据对比。点击上方公司名可切换其他公司
Xeris Biopharma Holdings, Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.1倍（$85.8M vs $75.5M），Xeris Biopharma Holdings, Inc.同比增速更快（42.8% vs 27.7%），过去两年Xeris Biopharma Holdings, Inc.的营收复合增速更高（45.3% vs 31.3%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Xeris Biopharma Holdings是一家专业生物制药企业，专注于开发和商业化罕见内分泌疾病、代谢疾病及皮肤病领域的靶向治疗药物，面向全球市场，致力于为缺医少药的患者群体提供易用性、可及性更高的治疗选择。
PBYI vs XERS — 直观对比
营收规模更大
XERS
是对方的1.1倍
$75.5M
营收增速更快
XERS
高出15.1%
27.7%
两年增速更快
XERS
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $85.8M |
| 净利润 | — | $11.1M |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | 19.5% |
| 净利率 | — | 12.9% |
| 营收同比 | 27.7% | 42.8% |
| 净利润同比 | — | 316.7% |
| 每股收益（稀释后） | $0.26 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIXERS
| Q4 25 | $75.5M | $85.8M | ||
| Q3 25 | $54.5M | $74.4M | ||
| Q2 25 | $52.4M | $71.5M | ||
| Q1 25 | $46.0M | $60.1M | ||
| Q4 24 | $59.1M | $60.1M | ||
| Q3 24 | $80.5M | $54.3M | ||
| Q2 24 | $47.1M | $48.1M | ||
| Q1 24 | $43.8M | $40.6M |
净利润PBYIXERS
| Q4 25 | — | $11.1M | ||
| Q3 25 | $8.8M | $621.0K | ||
| Q2 25 | $5.9M | $-1.9M | ||
| Q1 25 | $3.0M | $-9.2M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | $20.3M | $-15.7M | ||
| Q2 24 | $-4.5M | $-15.0M | ||
| Q1 24 | $-4.8M | $-19.0M |
毛利率PBYIXERS
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYIXERS
| Q4 25 | 22.7% | 19.5% | ||
| Q3 25 | 17.6% | 9.0% | ||
| Q2 25 | 12.7% | 6.3% | ||
| Q1 25 | 8.7% | -5.1% | ||
| Q4 24 | 22.6% | 2.8% | ||
| Q3 24 | 27.4% | -23.8% | ||
| Q2 24 | -4.6% | -17.0% | ||
| Q1 24 | -5.3% | -35.1% |
净利率PBYIXERS
| Q4 25 | — | 12.9% | ||
| Q3 25 | 16.2% | 0.8% | ||
| Q2 25 | 11.2% | -2.7% | ||
| Q1 25 | 6.5% | -15.3% | ||
| Q4 24 | — | -8.5% | ||
| Q3 24 | 25.2% | -29.0% | ||
| Q2 24 | -9.6% | -31.2% | ||
| Q1 24 | -11.0% | -46.7% |
每股收益（稀释后）PBYIXERS
| Q4 25 | $0.26 | $0.07 | ||
| Q3 25 | $0.17 | $0.00 | ||
| Q2 25 | $0.12 | $-0.01 | ||
| Q1 25 | $0.06 | $-0.06 | ||
| Q4 24 | $0.40 | $-0.02 | ||
| Q3 24 | $0.41 | $-0.11 | ||
| Q2 24 | $-0.09 | $-0.10 | ||
| Q1 24 | $-0.10 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $111.0M |
| 总债务越低越好 | $22.7M | $220.3M |
| 股东权益账面价值 | $130.3M | $13.7M |
| 总资产 | $216.3M | $383.5M |
| 负债/权益比越低杠杆越低 | 0.17× | 16.10× |
8季度趋势，按日历期对齐
现金及短期投资PBYIXERS
| Q4 25 | $97.5M | $111.0M | ||
| Q3 25 | $94.4M | $91.6M | ||
| Q2 25 | $96.0M | $59.3M | ||
| Q1 25 | $93.2M | $58.4M | ||
| Q4 24 | $101.0M | $71.6M | ||
| Q3 24 | $96.7M | $69.4M | ||
| Q2 24 | $96.8M | $77.6M | ||
| Q1 24 | $107.2M | $87.4M |
总债务PBYIXERS
| Q4 25 | $22.7M | $220.3M | ||
| Q3 25 | $34.0M | $219.5M | ||
| Q2 25 | $45.3M | $218.6M | ||
| Q1 25 | $56.7M | $229.8M | ||
| Q4 24 | $68.0M | $232.1M | ||
| Q3 24 | $79.3M | $216.2M | ||
| Q2 24 | $90.7M | $230.5M | ||
| Q1 24 | $102.0M | $229.7M |
股东权益PBYIXERS
| Q4 25 | $130.3M | $13.7M | ||
| Q3 25 | $115.3M | $-861.0K | ||
| Q2 25 | $104.7M | $-19.3M | ||
| Q1 25 | $97.1M | $-35.1M | ||
| Q4 24 | $92.1M | $-29.6M | ||
| Q3 24 | $71.1M | $-28.3M | ||
| Q2 24 | $48.5M | $-19.3M | ||
| Q1 24 | $51.0M | $-9.2M |
总资产PBYIXERS
| Q4 25 | $216.3M | $383.5M | ||
| Q3 25 | $202.9M | $370.2M | ||
| Q2 25 | $194.9M | $334.7M | ||
| Q1 25 | $196.2M | $315.5M | ||
| Q4 24 | $213.3M | $323.1M | ||
| Q3 24 | $220.7M | $321.1M | ||
| Q2 24 | $205.0M | $331.7M | ||
| Q1 24 | $214.1M | $336.6M |
负债/权益比PBYIXERS
| Q4 25 | 0.17× | 16.10× | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $20.0M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | — |
| 自由现金流率自由现金流/营收 | 19.1% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 1.81× |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYIXERS
| Q4 25 | $14.4M | $20.0M | ||
| Q3 25 | $9.7M | $18.4M | ||
| Q2 25 | $14.1M | $182.0K | ||
| Q1 25 | $3.6M | $-10.0M | ||
| Q4 24 | $15.6M | $2.0M | ||
| Q3 24 | $11.0M | $-8.3M | ||
| Q2 24 | $1.0M | $-10.3M | ||
| Q1 24 | $11.2M | $-20.3M |
自由现金流PBYIXERS
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | — | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
自由现金流率PBYIXERS
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
资本支出强度PBYIXERS
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
现金转化率PBYIXERS
| Q4 25 | — | 1.81× | ||
| Q3 25 | 1.10× | 29.68× | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
XERS
| Products | $83.4M | 97% |
| Other | $2.4M | 3% |
